Open AccessP945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON‐BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE‐DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS
Author(s) -
Quach H.,
Parmar G.,
Ocio E. M.,
Prince H. M.,
Oriol A.,
Tsukada N.,
Sunami K.,
Bories P.,
Karanes C.,
Madan S.,
Semiond D.,
Inchauspe M.,
Macé S.,
Musholt P. B.,
Suzan F.,
Moreau P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846648.34152.68
Subject(s) - medicine , pomalidomide , pharmacokinetics , refractory (planetary science) , tolerability , adverse effect , dexamethasone , interim analysis , clinical trial , lenalidomide , physics , astrobiology